1477 Share Price Performance
HK$0
-5.56 (-100.00%)
Price HK$0
Share Pricen/a
Is Ocumension Therapeutics (HKG:1477) A Risky Investment?
Oct 08
Ocumension Therapeutics Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
1477 Community Narratives
There are no narratives available yet.
There are no community narratives available.
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Ocumension Therapeutics Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -0.31
- 42.58%
- -45.84%
- 1.3%
About 1477
- Founded
- 2017
- Employees
- 505
- CEO
- WebsiteView website
Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. It discovers, develops, and commercializes therapies for ophthalmic patients. Its portfolio includes products and drugs for the treatment of chronic non-infectious uveitis, infective and allergic conjunctivitis, diabetic macular edema, dry eye, glaucoma and ocular hypertension, postoperative inflammation, choroidal neovascularization, bacterial conjunctivitis, retinitis pigmentosa, age-related macular degeneration, cornea graft rejection, myopia, and optic neuritis. The company was founded in 2017 and is based in Suzhou, the People's Republic of China.
